Radiopharm (RADX) Sees Slight Pessimism From Analysts
Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B.
Radiopharm Theranostics Limited (RADX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | SilverArc Capital Devesh Gandhi | 187,406 | $1,034,481 | 0.14% | |
| 2. | VGI Partners Robert M. P. Luciano | 90,909 | $501,818 | 0.04% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,191 | $100,414 | 0% | |
| 2. | 16,000 | $88,320 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
7 Best ASX Stocks to Buy Right Now
While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in the opposite direction.
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now.
12 Best Australian Stocks to Buy Right Now
Australia’s S&P/ASX 200 index advanced 0.53% on Thursday to close at 8,873.80, with investors buoyed by gains in the banking sector, amid robust earnings and renewed hopes for further interest rate ...
11 Best Australian Stocks to Buy According to Analysts
The tariffs announced by the United States have challenged the economic and market outlooks around the globe.